Clinical Trials
14 trialsNCT00590915 2026-01-23
EMTP
Phoenix Children's Hospital
No longer available
NCT01881334 2025-11-20
Expanded Access to T-cell Depleted Haplo-Identical Stem Cells for Patients Receiving Haplo-Identical and Unrelated Cord Blood Transplants
Duke University
Available
NCT04008524 2025-08-06
A Clinical Study of CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies
Institute of Hematology & Blood Diseases Hospital, China
Available
NCT03145545 2025-05-22
Expanded Access Protocol Using Alpha/Beta T and CD19+ Depleted PBSC
Children's Hospital of Philadelphia
Available
NCT02158767 2025-03-12
Access Protocol. Infusion of CD34+ Enriched, T Cell Depleted Hematopoietic Stem Cell Grafts.
Case Comprehensive Cancer Center
No longer available
NCT05215405 2025-02-03
Expanded Access Program of Venetoclax and Navitoclax for Pediatric Patients with Relapsed or Refractory ALL or LL
University of Texas Southwestern Medical Center
No longer available
NCT02258490 2022-03-15
Expanded Use of G-CSF Mobilized Donor CD34+ Selected Cells for Allogeneic Transplantation
Emory University
No longer available
NCT03594162 2021-12-03
Compassionate Use of CAR T Cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch
UNC Lineberger Comprehensive Cancer Center
No longer available
NCT01200017 2021-05-27
Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant
University of California, San Francisco
No longer available
NCT01869803 2018-03-02
Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia
Wake Forest University Health Sciences
Approved for marketing
NCT00423826 2016-02-29
Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
Barbara Ann Karmanos Cancer Institute
No longer available
NCT00481559 2014-01-17
Treatment Protocol of Voraxaze for Patients Experiencing or at Risk of Methotrexate Toxicity
BTG International Inc.
Approved for marketing
NCT01549548 2013-03-15
Compassionate Use Ponatinib
OHSU Knight Cancer Institute
No longer available
NCT00854841 2009-03-03
The Randomized Study of Dasatinib and High-Dose Imatinib (600mg) in Suboptimal Responder
Pusan National University Hospital
Available